/
We are a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue utilizing our platform technologies. Our lead product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to abl…
$6.85
+$0.07 (+1.03%)
EOD Jul 17, 2026
The business is unprofitable at the operating level (-256.27% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 50.7% YoY with margins expanding 53.3pp.
Negative free cash flow of -$38M. The business is consuming cash, not generating it.
5.5x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$19M
▲ +50.7% YoY
Net Income (TTM)
-$39M
▼ -53.0% YoY
Op. Margin
-202.56%
▲ +53.3pp YoY
ROIC
-52.82%
▲ +2.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$39M
▼ -63.7% YoY
Op. Cash Flow (TTM)
-$39M
▼ -62.9% YoY
Net Debt
-$38M
Net Cash Position
Cash & Equiv.
$50M
Continue Research
At a P/E of 5.5, Profound Medical (PROF)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Profound Medical scores 50/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Profound Medical scores 50 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -202.6% operating margin and a -52.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh PROF's valuation and scores 50/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.